C.R. Bard, Inc. (NYSE:BCR)
| CAPS Rating |
|
|---|---|
| Open | $91.72 |
| Previous Close | $92.31 |
| Daily Range | $91.41 - $95.70 |
| 52-Week Range | $80.80 - $113.84 |
| Market Cap | $8.29B |
| P/E Ratio | 23.10 |
| Dividend (Yield) | 0.76 (0.80%) |
| Volume | 3,066,500 |
| Average Daily Volume | 0 |
BCR
VS S&P 500 (SPY)
How do you think BCR will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BCR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BCR News and Commentary
- Earnings Scorecard: Covidien - Analyst Blog – NASDAQ
- AngioDynamics to Buy Navilyst - Analyst Blog – NASDAQ
- Bard Tops in 4Q, Charges Crimp Net - Analyst Blog – NASDAQ
- C.R. Bard Beats Analyst Estimates on EPS – The Motley Fool
- Covidien's Solitaire Ok'd for Trial - Analyst Blog – NASDAQ
- Earnings Preview: C.R. Bard - Analyst Blog – NASDAQ
- AngioDynamics Cuts View on Recall - Analyst Blog – NASDAQ
- Covidien EPS Tops, Snips Sales View - Analyst Blog – NASDAQ
- Earnings Preview: Covidien - Analyst Blog – NASDAQ
- Does Boston Scientific Pass Buffett's Test? – The Motley Fool
- Covidien Recalls Duet TRS - Analyst Blog – NASDAQ
- Ex-Dividend Stocks On January 19, 2012 – Blog at The Motley Fool
- Retaining AngioDynamics at Neutral - Analyst Blog – NASDAQ
- Covidien Wraps up BARRX Buy - Analyst Blog – NASDAQ
- AngioDynamics Beats, Tweaks View - Analyst Blog – NASDAQ
- FDA Orders Post-Market Testing Of Surgical Mesh Amid Safety Concerns – SmartMoney
- CR Bard Passes This Key Test – The Motley Fool
- AngioDynamics Concludes Enrollment - Analyst Blog – NASDAQ
- Bard Buys Lutonix for $225M - Analyst Blog – NASDAQ
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
RSS Headlines
Fool UK
